Clinical Trial Update: LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

View source ↗

Summary

The document reports lorlatinib-associated hyperlipidemia in ALK-positive non-small cell lung cancer and notes monitoring considerations in the trial. It highli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Non-Small Cell Lung Cancer, Hyperlipidemia | Status: ENROLLING_BY_INVITATION